Skip Navigation

Europace 2000 2(2):160-162; doi:10.1053/eupc.1999.0083
© 2000 by European Society of Cardiology
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schulte, B.
Right arrow Articles by Neuzner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulte, B.
Right arrow Articles by Neuzner, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Detection of ventricular fibrillation in implantable defibrillators with automatic gain control amplifiers

Effects of programming sensitivity

B. Schulte, J. Sperzel, T. Schwarz, H.F. Pitschner, G. Strupp1 and J. Neuzner

Kerckhoff-Clinic Bad Nauheim, Germany; 1Medical Clinic I Fulda, Germany

AIMS: In newer implantable cardioverter–defibrillators with automatic gain control amplifiers the maximum possible sensitivity is programmed with the aim of securing optimal detection of ventricular fibrillation. This study was designed to prove that a reduction in maximum sensitivity is safe with respect to appropriate sensing of ventricular fibrillation, while avoiding sensing of extracardiac signals.

METHODS AND RESULTS: Forty-two consecutive patients, undergoing defibrillator implantation/replacement with programmable maximum auto-gain sensing sensitivity (Ventak Mini IIITM, Ventak AVTM, Guidant, St. Paul, MN, U.S.A.), were prospectively investigated. Thirty-four patients were implanted with a dual-coil lead system, providing integrated bipolar sensing (EndotakTM, Guidant, St. Paul, MN, U.S.A.), eight patients received a single-coil lead system with true bipolar sensing (SprintTM, Medtronic, Minneapolis, MN, U.S.A.). During device implantation and pre-discharge testing, arrhythmia detection times of induced ventricular fibrillation were compared at programmed maximum (0·18 mV) and minimum (0·43 mV) sensitivity in a randomized manner. Seventy-six induced episodes of ventricular fibrillation were analysed. The mean arrhythmia detection times did not differ between the programmed sensing levels (maximum sensitivity: 1612±307 ms, vs minimal sensitivity: 1602±330 ms;P=ns). The results were not affected by the type of implanted lead system (integrated bipolar versus true bipolar sensing).

CONCLUSION: In the implantable defibrillator devices, reduction in maximum sensitivity did not impair the detection of induced episodes of ventricular fibrillation.

Key Words: Implantable defibrillator, automatic gain control, programmable sensitivity

Correspondence: Jörg Neuzner MD, FESC, Dept. of Cardiology, Kerckhoff-Clinic, Bad Nauheim, Beneke Strasse 2–8, D-61231 Bad Nauheim, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.